Administration of optimal biological dose and schedule of interferon α combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice

Clinical Cancer Research

Volumn 9, Issue 5, 2003, Pages 1858-1867

  Solorzano, Carmen C ^a   Hwang, Rosa ^a   Baker, Cheryl H ^a   Bucana, Corazon D ^a   Pisters, Peter W ^a   Evans, Douglas B ^a   Killion, Jerald J ^a   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BASIC FIBROBLAST GROWTH FACTOR; CD31 ANTIGEN; CYCLINE; GELATINASE B; GEMCITABINE; GENZAR; INTERLEUKIN 8; RECOMBINANT ALPHA2A INTERFERON; SODIUM CHLORIDE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MICROVASCULATURE; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PANCREAS CARCINOMA; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DIVISION; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMPLANTS, EXPERIMENTAL; INTERFERON-ALPHA; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; SURVIVAL RATE; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0038666255     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Warshaw, A. L., and Fernandez-del Castillo, C. Pancreatic carcinoma. N. Eng. J. Med., 326: 455-465, 1992.
2. Evans, D. B., Abbruzzese, J. L., and Willet, C. G. Cancer of the pancreas. In: V. deVita, S. Hellman, and S. A. Rosenberg (eds.), Principles and Practice of Oncology, pp. 1126-1160. Philadelphia: J. B. Lippincott, 2000.
3. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer statistics, 2002. CA Cancer J. Clin., 52: 23-47, 2002.
4. Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15: 2403-2413, 1997.
5. Moore, M. Activity of gemcitabine in patients with advanced pancreatic carcinoma: a review. Cancer (Phila.), 78: 633-638, 1996.
6. Isaacs, A., and Lindenmann, J. Virus interference. J. Interferon Res., 7: 429-438, 1987.
7. Hertzog, P. J., Hwang, S. Y., and Kola, I. Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol. Reprod. Dev., 39: 226-232, 1994.
8. Gutterman, J. U. Cytokine therapeutics: lessons from interferon-α Proc. Natl. Acad. Sci. USA, 91: 1198-1205, 1994.
9. Thomas, H., and Balkwill, F. R. Effects of interferons and other cytokines on tumors in animals: a review. Pharmacol. Ther., 52: 307-330, 1991.
10. Fabra, A., Nakajima, M., Bucana, C. D., and Fidler, I. J. Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice. Differentiation, 52: 101-110, 1992.
11. Gohji, K., Fidler, I. J., Tsan, R., Radinsky, R., von Eschenbach, A. C., Tsuruo, T., and Nakajima, M. Human recombinant interferons-β and -γ decrease gelatinase production and invasion by human KG-2 renal carcinoma cells. Int. J. Cancer, 58: 380-384, 1994.
12. Kato, N., Nawa, A., Tamakoshi, K., Kikkawa, F., Suganuma, N., Okamoto, T., Goto, S., Tomoda, Y., Hamaguchi, M., and Nakajima, M. Suppression of gelatinase production with decreased invasiveness of choriocarcinoma cells by human recombinant interferon-β. Am. J. Obstet. Gynecol., 172: 601-606, 1995.
13. Singh, R. K., Gutman, M., Llansa, N., and Fidler, I. J. Interferon-β prevents the upregulation of interleukin-8 expression in human melanoma cells. J. Interferon Cytokine Res., 16: 577-584, 1996.
14. Oliveira, I. C., Sciavolino, P. J., Lee, T. H., and Vilcek, J. Downregulation of interleukin-8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc. Natl. Acad. Sci. USA, 89: 9049-9053, 1992.
15. Sparano, J. A., Lipsitz, S., Wadler, S., Hansen, R., Bushunow, P. W., Kirkwood, J., Flynn, P. J., Dutcher, J. P., and Benson, A. B. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-α in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. Am. J. Clin. Oncol., 19: 546-551, 1996.
16. Papapetropoulos, A., Piccardoni, P., Cirino, G., Bucci, M., Sorrentino, R., Cicala, C., Johnson, K., Zachariou, V., Sessa, W. C., and Altieri, D. C. Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. Proc. Natl. Acad. Sci. USA, 95: 4738-4742, 1998.
17. Wagener, D. J., Wils, J. A., Kok, T. C., Planting, A., Couvreur, M. L., and Baron, B. Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with α-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial. Eur. J. Cancer, 38: 648-653, 2002.
18. Nukui, Y., Picozzi, V. J., and Traverso, L. W. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am. J. Surg., 179: 367-371, 2000.
19. Wills, R. J. Clinical pharmacokinetics of interferons. Clin. Pharmacokinet., 19: 390-399, 1990.
20. Singh, R. K., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N., and Fidler, I. J. Interferons α and β downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA, 92: 4562-4566, 1995.
21. Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., and Fidler, I. J. Interferon-α-mediated downregulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res., 5: 2726-2734, 1999.
22. Bruns, C. J., Harbison, M. T., Kuniyasu, H., Eue, I., and Fidler, I. J. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia, 1: 50-62, 1999.
23. Fan, D., Poste, G., Seid, C., Earnest, L. E., Bull, T., Clyne, R. K., and Fidler, I. J. Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol. Investig. New Drugs, 12: 185-195, 1994.
24. Vecchi, A., Garlanda, C., Lampugnani, M. G., Resnati, M., Matteucci, C., Stoppacciaro, A., Schnurch, H., Risau, W., Ruco, L., and Mantovani, A. Monoclonal antibodies specific for endothelial cells of mouse blood vessels: their application in the identification of adult and embryonic endothelium. Eur. J. Cell Biol., 63: 247-254, 1994.
25. Bruns, C. J., Solorzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R., Fan, D., Abbruzzese, J., Traxler, P., Buchdunger, E., Radinsky, R., and Fidler, I. J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res., 60: 2926-2935, 2000.
26. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
27. Shi, S. R., Key, M. E., and Kalra, K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem., 39: 741-748, 1991.
28. Fidler, I. J., and Ellis, L. M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79: 185-188, 1994.
29. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
30. Singh, R. K., Llansa, N., Bucana, C. D., Sanchez, R., Koura, A., and Fidler, I. J. Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells. Cell Growth Differ., 7: 397-404, 1996.
31. Vermeulen, P. B., Dirix, L. Y., Martin, M., Lemmens, J., and Van Oosterom, A. T. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon-α-2b. J. Natl. Cancer Inst. (Bethesda), 89: 1316-1317, 1997.
32. Dinney, C. P., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., Bucana, C. D., and Fidler, I. J. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res., 58: 808-814, 1998.
33. Ellis, L. M., and Fidler, I. J. Angiogenesis and metastasis. Eur. J. Cancer, 32A: 2451-2460, 1996.
34. Nicholson, S. E., and Hilton, D. J. The SOCS proteins: a new family of negative regulators of signal transduction. J. Leukocyte Biol., 63: 665-668, 1998.
35. Nicola, N. A., Nicholson, S. E., Metcalf, D., Zhang, J. G., Baca, M., Farley, A., Willson, T. A., Starr, R., Alexander, W., and Hilton, D. J. Negative regulation of cytokine signaling by the SOCS proteins. Cold Spring Harbor Symp. Quant. Biol., 64: 397-404, 1999.
36. Narazaki, M., Fujimoto, M., Matsumoto, T., Morita, Y., Saito, H., Kajita, T., Yoshizaki, K., Naka, T., and Kishimoto, T. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin-6 signaling. Proc. Natl. Acad. Sci. USA, 95: 13130-13134, 1998.
37. Tedjariti, S., Baker, C. H., Apte, S., Huang, S., Wolf, J. K., Killion, J. J., and Fidler, I. J. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon-α combined with paclitaxel. Clin. Cancer Res., 8: 2412-2422, 2002.
38. Yamazaki, K., Nagao, T., Yamaguchi, T., Saisho, H., and Kondo, Y. Expression of basic fibroblast growth factor (FGF-2)-associated with turnout proliferation in human pancreatic carcinoma. Virchows Arch., 431: 95-101, 1997.
39. Pepper, M. S., Ferrara, N., Orci, L., and Montesano, R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun., 189: 824-831, 1992.
40. Fujio, Y., and Walsh, K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem., 274: 16349-16354, 1999.
41. Fidler, I. J. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J. Natl. Cancer Inst. (Bethesda), 93: 1040-1041, 2001.